Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 107 posts found.

bms

BMS’ Opdivo gets a potential first-line boost in kidney cancer

September 8, 2017
Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …

News
bms_4

BMS hit by clinical trial hold from FDA

September 7, 2017
Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical

The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …

News
opdivo_1_1

BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer

August 16, 2017
Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …

News
scotland_flag

SMC reverses decision on Opdivo for kidney cancer

June 12, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo

The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …

News

England “really is not a good place” to get cancer, BMS UK General Manager says

April 24, 2017
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo

Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …

News
opdivo_1_1

NICE turns down BMS’ Opdivo for head and neck cancer

April 11, 2017
Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo

Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …

News
800px-university_of_pittsburgh_tablet2

Immune system influences immunotherapy effectiveness, research shows

April 3, 2017
Research and Development, Sales and Marketing immunotherapy, nivolumab, opdivo

Preliminary research conducted at the University of Pittsburgh Cancer Institute (UPCI) has discovered a link between levels of certain immune …

News
shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
opdivo_1_1

NICE recommends against Opdivo for classical Hodgkin lymphoma

March 15, 2017
Research and Development, Sales and Marketing BMS, classical Hodgkin Lymphoma, opdivo

The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab) …

News
shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

Feature
pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News
keytruda3-web

MSD aims to get the jump on BMS treating bladder cancer

February 6, 2017
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News

BMS receives $625 million patent settlement boost from Merck

January 23, 2017
Sales and Marketing BMS, MSD, Merck, keytruda, opdivo

Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …

News

Japan announces measure to crack down on drug pricing

December 20, 2016
Manufacturing and Production, Medical Communications Japan, Shinzo Abe, opdivo

Japan has committed to annual drug price reviews whilst also expanding the scope by which the prices are deemed to …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023